Literature DB >> 14503095

The effect of topical fluticasone on nasal nitric oxide levels in a patient with allergic rhinitis.

Cetin Vural1, Anil Gungor.   

Abstract

Nitric oxide (NO) in exhaled breath is produced primarily by the upper respiratory airway mucosa. The nasal output of this gas is increased in patients with allergic rhinitis. We performed a study on a 41-year-old nonsmoking male volunteer with allergic rhinitis to investigate the effect of fluticasone nasal spray on nasal NO output (VNO). A total of 28 nasal NO measurements from both nostrils were taken during the 2-month period of June and July 2002. During the second half of the study period (treatment phase), the patient took fluticasone in doses of 100 micrograms per nostril once a day. During the treatment phase, nasal NO measurements were taken 10 days after the initiation of treatment. In addition, we also recorded the patient's nasal symptom scores and the grass pollen counts in the greater Pittsburgh area. The patient's mean VNO was 989.9 nl/min prior to treatment and 787.7 nl/min following treatment--a statistically significant 20.4% decrease (p < 0.01). The findings of our study support the observation that topical nasal steroid treatment decreases NO production in sinonasal mucosa.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14503095

Source DB:  PubMed          Journal:  Ear Nose Throat J        ISSN: 0145-5613            Impact factor:   1.697


  2 in total

1.  Nasal NO measurement by direct sampling from the nose during breathhold: Aspiration flow, nasal resistance and reproducibility.

Authors:  V M D Struben; M H Wieringa; C J Mantingh; J C de Jongste; L Feenstra
Journal:  Eur Arch Otorhinolaryngol       Date:  2006-05-19       Impact factor: 2.503

2.  Nasal obstruction and palate-tongue position on sleep-disordered breathing.

Authors:  Hyo Yeol Kim; Jong In Jeong; Hun-Jong Dhong; Jung Heob Sohn; Sang Duk Hong; Joon Ho Kim; Seong Yun Jang; Yong Gi Jung; Seung-Kyu Chung
Journal:  Clin Exp Otorhinolaryngol       Date:  2013-11-29       Impact factor: 3.372

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.